Synonym(s):
nadide; NAD+; 53-84-9; coenzyme I; beta-NAD; Codehydrase I; nicotinamide adenine dinucleotide; beta-NAD+; Cozymase I; Codehydrogenase I; diphosphopyridine nucleotide; beta-Diphosphopyridine nucleotide; beta-nicotinamide adenine dinucleotide; COZYMASE; Nicotinamide dinucleotide; CO-I; Enzopride; NAD; NAD zwitterion; Oxidized diphosphopyridine nucleotide; CO-1; Pyridine, nucleotide diphosphate; Adenine-nicotinamide dinucleotide; Nicotineamide adenine dinucleotide; Nicotinamide-adenine dinucleotide; beta-DPN; Nadidum [INN-Latin]; Nadida [INN-Spanish]; C21H27N7O14P2; MFCD00036253; nicotinamide adenine dinucleotide oxidized; beta-Diphosphopyridinenucleotide; CHEBI:44215; b-Nicotinamide adenine dinucleotide; BRN 3584133; UNII-0U46U6E8UK; diphosphopyridine nucleotide oxidized; NAD trihydrate; 3-Carbamoyl-1-beta-D-ribofuranosylpyridinium hydroxide, 5'-ester with adenosine 5'-pyrophosphate, inner salt; NAD-oxidized; Nicotinamide adenine dinucleotide (NAD); Nicotinamide-Adenine-Dinucleotide; NSC 20272; DPN-ox; Endopride; Adenosine 5'-(trihydrogen diphosphate), P'-5'-ester with 3-(aminocarbonyl)-1-beta-D-ribofuranosylpyridinium hydroxide, inner salt; DPN+; Nadidum; Nadida; Adenosine 5'-(trihydrogen diphosphate), P'-5'-ester with 3-(aminocarbonyl)-1-beta-D-ribofuranosylpyridinium, inner salt; 0U46U6E8UK; NAD Lithium salt; 1-((2R,3R,4S,5R)-5-((((((((2R,3S,4R,5R)-5-(6-Amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)oxy)oxidophosphoryl)oxy)methyl)-3,4-dihydroxytetrahydrofuran-2-yl)-3-carbamoylpyridin-1-ium; Nadide [USAN:INN:BAN:JAN]; 64417-72-7; Pyridinium, 3-carbamoyl-1-beta-D-ribofuranosyl-, hydroxide, 5'-ester with adenosine 5'-5'-(trihydrogen pyrophosphate), inner salt; EINECS 200-184-4; beta-Nicotinamide adenine dinucleotide trihydrate; NSC20272; CAS-53-84-9; NCGC00016240-01; b-DPN; b-NAD; beta-Nicotinamide adenine dinucleotide hydrate; b-NAD, oxidised form; C-NAD; beta-NAD, oxidised form; [adenylate-32-P]-NAD; Carbonyl [14C] NAD+; EC 200-184-4; NAD, Grade I, free acid; [adenylate-32-P]-NAD+; DSSTox_CID_25236; DSSTox_RID_80768; NAD, Grade II, free acid; DSSTox_GSID_45236; 5-26-16-00399 (Beilstein Handbook Reference); SCHEMBL131544; SPECTRUM1500419; Pyridine nucleotide diphosphate; GTPL2451; CHEMBL1234613; DTXSID2045236; HMS500J11; Nicotinamide Adinine Dinucleotide; [14C] NAD+; [32P] NAD+; BDBM213227; HMS2091H06; HMS2097E04; HMS3714E04; Pharmakon1600-01500419; EX-A3535; HY-B0445; Tox21_110321; 6614AF; CCG-40114; NSC757121; s2518; AKOS015892319; beta-nicotinamide adenine din-ucleotide; CM11026; DB14128; NSC-757121; .beta.-Nicotinamide adenine dinucleotide; NCGC00178839-01; NCGC00178839-02; NCGC00178839-03; NCGC00178839-08; [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate; Adenosine 5'-(trihydrogen diphosphate), 5'-5'-ester with 3-(aminocarbonyl)-1-beta-D-ribofuranosylpyridinium, hydroxide, inner salt; AS-14652; M041; SBI-0051451.P003; AB00513910; D0919; beta-Nicotinamide adenine dinucleotide, reduced; AB00052048_03; b-Nicotinamide adenine dinucleotide hydrate (NAD); Nicotinamide adenine dinucleotideNAD+mono sodium salt; beta-Nicotinamide adenine dinucleotide hydrate, >=99%; Q12499775; F45C0D6C-DA87-47BE-9975-7A5DE9CCB985; beta-Nicotinamide adenine dinucleotide hydrate, >=95% (HPLC); beta-Nicotinamide adenine dinucleotide, pkg of 10 mg (per vial); beta-Nicotinamide adenine dinucleotide, pkg of 20 mg (per vial); beta-Nicotinamide adenine dinucleotide, pkg of 50 mg (per vial); beta-Nicotinamide adenine dinucleotide hydrate, >=98%, BioUltra, from yeast; beta-Nicotinamide adenine dinucleotide hydrate, Grade AA-1, >=95% (HPLC); 3-Carbamoyl-1-D-ribofuranosylpyridinium hydroxide 5'-ester with adenosine 5'-pyrophosphate; beta-Nicotinamide adenine dinucleotide hydrate, purified by column chromatography, >=99%; beta-Nicotinamide adenine dinucleotide hydrate, Vetec(TM) reagent grade, >=96.5%; [(3S,2R,4R,5R)-5-(6-Aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl {[(3S,2R,4R,5R)-5-(3-carbamoylpyridyl)-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxyphosphoryl) hydrogen phosphate; [(3S,2R,4R,5R)-5-(6-Aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl {[(3S,2R,4R,5R)-5-(3-carbamoylpyridyl)-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxyphosphoryl)hydrogen phosphate; [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl]methoxy-hydroxy-phosphoryl] [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl]methyl hydrogen phosphate; 3-Carbamoyl-1-beta-D-ribofuranosylpyridinium hydroxide 5'-ester with adenosine 5'-pyrophosphate inner salt; 3-Carbamoyl-1-beta-delta-ribofuranosylpyridinium hydroxide 5'-ester with adenosine 5'-pyrophosphate inner salt; 3-Carbamoyl-1-delta-ribofuranosylpyridinium hydroxide 5'-ester with adenosine 5'-pyrophosphate; Adenosine 5'-(trihydrogen diphosphate), P'->5'-ester with 3-(aminocarbonyl)-1-beta-D-ribofuranosylpyridinium, inner salt; Adenosine 5'-(trihydrogen diphosphate), P'.fwdarw.5'-ester with 3-(aminocarbonyl)-1-beta-D-ribofuranosylpyridinium, inner salt; Adenosine 5'-(trihydrogen diphosphate-P-32P), P'>5'-ester with 3-(aminocarbonyl)-1-beta-D-ribofuranosylpyridinium, inner salt (9CI); beta-Nicotinamide adenine dinucleotide hydrate, >=96.5% (HPLC), >=96.5% (spectrophotometric assay), from yeast; beta-Nicotinamide adenine dinucleotide hydrate, cell culture tested, >=96.5% (HPLC), >=96.5% (spectrophotometric assay), from yeast; beta-Nicotinamide adenine dinucleotide hydrate, PharmaGrade, Manufactured under appropriate controls for use as a raw material in pharma or biopharmaceutical production.; beta-Nicotinamide adenine dinucleotide hydrate, Suitable for manufacturing of diagnostic kits and reagents; Pyridinium, 3-carbamoyl-1-b-D-ribofuranosyl-, hydroxide, 5'-5'-ester with adenosine 5'-(trihydrogen pyrophosphate), inner salt (8CI)